Search tips
Search criteria 


Logo of jvmsThe Journal of Veterinary Medical ScienceThis JournalFor AuthorsSubmissions
J Vet Med Sci. 2016 May; 78(5): 837–843.
Published online 2016 February 12. doi:  10.1292/jvms.15-0675
PMCID: PMC4905840

Serum matrix metalloproteinase 9 (MMP9) as a biochemical marker for wasting marmoset syndrome


Use of the common marmoset (Callithrix jacchus) as a non-human primate experimental animal has increased in recent years. Although wasting marmoset syndrome (WMS) is one of the biggest problems in captive marmoset colonies, the molecular mechanisms, biochemical markers for accurate diagnosis and a reliable treatment remain unknown. In this study, as a first step to finding biochemical marker(s) for the accurate diagnosis of WMS, we conducted blood cell counts, including hematocrit, hemoglobin and platelets, and examined serum chemistry values, including albumin, calcium and levels of serum matrix metalloproteinase 9 (MMP9), using a colony of marmosets with and without weight loss. MMP9 is thought to be an enzyme responsible for the degradation of extracellular matrix components and participates in the pathogenesis of inflammatory conditions, such as human and murine inflammatory bowel disease, which, like WMS, are characterized histologically by inflammatory cell infiltrations in the intestines. The values of hematocrit and hemoglobin and levels of serum albumin and calcium in the WMS group were significantly decreased versus the control group. The platelet values and serum MMP9 concentrations were increased significantly in the WMS group compared with the control group. MMP9 could be a new and useful marker for the diagnosis of WMS in addition to hematocrit, hemoglobin, serum albumin and calcium. Our results also indicate that MMP9 could be a useful molecular candidate for treatment.

Keywords: anemia, body weight, IBD, MMP9, wasting marmoset syndrome

The common marmoset (Callithrix jacchus) is a member of the New World monkeys that lives in northern and eastern Brazil. Relative to the Old World monkeys, such as macaques, they have several advantages, such as smaller body size, ease of handling, ease of breeding in captivity and absence of severe zoonotic issues. For these reasons, common marmosets have been used as experimental animals in many fields, such as reproductive biology, drug development and infectious disease [1, 3, 19, 21, 35, 36]. In addition, production of transgenic marmosets has become possible in recent years [33]. Since the Brain Mapping by Integrated Neurotechnologies for Disease Studies project (Brain/Minds project) started in Japan [26], the number of studies using common marmosets has increased, particularly in the field of brain sciences [21, 30].

Serious problems, typified by ‘wasting marmoset syndrome’ (WMS), are a concern in the management of common marmosets. The main symptoms of WMS are weight loss, decreased muscle mass and chronic diarrhea, and some studies reported that 28–60% of captive marmosets suffer from and 50–80% of deaths involve WMS [2, 5, 7, 12, 18, 19, 27]. Thus, WMS is one of the biggest problems in operating captive marmoset colonies. WMS is considered an inherent disease in this species, and no effective treatment has yet been established [19, 27].

Baxter et al. reported that lower body weight, under 325 g, identified most marmosets affected by WMS, and progressive body weight loss of 0.05% of the peak body weight per day identified 100% of marmosets affected by WMS [2]. Thus, a presumptive diagnosis of WMS can be made based on this, but the molecular mechanisms involved in the disease remain unclear.

In several reports, it was mentioned that the main disease state in WMS is an inflammatory bowel disease (IBD), anchored by chronic enteritis [2, 19, 25]. In humans, IBDs, as represented by Crohn’s disease and ulcerative colitis, are intractable diseases, and no curative treatment is yet known [9, 37]. Although a specific cause of IBD remains poorly defined, it is thought that interactions between genetic and environmental factors and uncontrollable autoimmunity cause the disease. Matrix metalloproteinase 9 (MMP9) is directly and indirectly involved in tissue remodeling, tumor growth and inflammation by means of controlling inflammatory cytokine activity [6, 8, 14, 20]. Activation of inflammatory cytokines and the involvement of MMP9 in IBD have been reported in humans and mice [11, 31, 34, 37, 38], but these molecular activities in WMS have yet to be characterized.

Thus, this study aimed to determine new target(s) for the diagnosis and therapy of WMS. We compared blood values of WMS animals with those of high-body-weight animals as a control group, using complete blood count (CBC), serum chemistry tests and a serum MMP9 concentration test.


Animals: The research was approved and overseen by the animal experiments committee of RIKEN (Wako, Japan) and was conducted in accordance with the Institutional Guidelines for Experiments using Animals.

Common marmosets were reared at the RIKEN Brain Science Institute (Wako, Japan), maintained at 27°C and 50% humidity on a 12/12-hr light/dark cycle. All marmosets in this study were chosen from animals between 2 and 6 years old. Marmosets were allowed ad libitum access to water and food pellets (CMS-1M, Clea Japan Inc., Tokyo, Japan) with added vitamin C, D, calcium and acidophilus. Hot water and comb honey were also added to soften the pellets and to improve the animals’ preference for the food. Animals were given a piece of Calorie Mate (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) or castella (Castella, Yamazaki Baking Co., Ltd., Tokyo, Japan) as a treat.

WMS animals were determined according to a previous report [2]. Briefly, individuals with body weights less than 325 g with 0.05% body weight loss per day were defined as the WMS group (n=7). Individuals with body weight higher than 375 g (a median value of 350–400 g was reported as the average weight of adult marmosets [35]), with 0.036% weight gain per day (average weight gain ratio of normal marmosets reported in [2]), were defined as the control group (n=7). The highest body weight was obtained from laboratory records. Body weight, the highest body weight, current body weight/the highest body weight ratio and gain/loss ratio per day are listed in Table 1.

Table 1.
Sex, age, body weight, the highest body weight, current body weight/the highest body weight ratio and body weight gain/loss ratio per day in individual animals are represented

Appearance check: First, all animals underwent an appearance check, including fur and posture (with or without unkempt fur, pale face, undervitalized appearance, alopecia, curved back, pigeon-toed and stiff movement).

Blood collection: Blood samples were drawn from an individual’s femoral vein using 26-gauge needles. For the duration of blood collection, animals were under manual retention. Part of the collected blood was used for CBC. The rest of the blood was centrifuged (1,800×g, 20 min and 4°C) after standing for 1 hr at room temperature. The purified serum was stored at −80°C until used for serum chemistry and serum MMP9 concentration tests.

CBC and serum chemistry tests: A CBC analysis, including white blood cells, red blood cells, hematocrit, hemoglobin, platelets, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC), was performed using Celltac α (MEK-6450, NIHON KOHDEN Co., Ltd., Tokyo, Japan). A serum chemistry panel (albumin and calcium) was performed using a Drychem 4,000 system (FUJIFILM Co., Ltd., Tokyo, Japan).

Serum MMP9 concentration test: We performed serum tests of MMP9 concentrations using commercial ELISA kits (Quantikine ELISA Human MMP-9, SMP900; R&D Systems, Inc., Minneapolis, MN, U.S.A.).

Anatomical study: Marmoset colons were dissected after perfusion with saline followed by 4% paraformaldehyde under deep anesthesia. The dissected colons were fixed with Tissue Fixative (Genostaff, Co., Ltd., Tokyo, Japan), then embedded in paraffin wax and sectioned at 6 µm for hematoxylin and eosin (HE) staining.

Statistical analysis: Two-tailed Mann-Whitney U-tests were used to compare the WMS and control groups, and Spearman’s rank coefficient (two tailed) was used to measure correlations between body weight and each data point (GraphPad Prism, ver. 6 for Windows; GraphPad Software Inc., La Jolla, CA, U.S.A.). Data are presented as means ± standard error of the mean (SEM). Results were considered significant at 5% or less probability of error.


Appearance check: Pigeon-toe, which was considered to be caused by stiff movement in the hind limb (Fig. 1A and 1B), and alopecia (Fig. 1C), especially on the tail base (Fig. 1D), were observed in all seven animals in the WMS group. Neither abnormality was observed in any of the seven animals in the control group.

Fig. 1.
Marmosets in the WMS group show alopecia and pigeon toe. (A) Overall body posture of a marmoset in the WMS group. (B) Magnification of the white square in A. Hind limbs are pigeon-toed. (C) Appearance of a marmoset in the WMS group. Red arrow indicates ...

CBC: The hematocrit and hemoglobin values differed significantly between the animals in the two groups (P<0.01, Fig. 2A, and P<0.01, Fig. 2B, respectively). The mean hematocrit values of the WMS group and the control group were 24.8 ± 1.92% and 40.7 ± 1.48%, respectively. The mean hemoglobin values of the WMS group and the control group were 8.26 ± 0.808 g/dl and 12.97 ± 0.451 g/dl, respectively. Significant correlations between body weight and hematocrit and hemoglobin values were observed (P<0.01, rs=0.837, Fig. 2C, and P<0.01, rs=0.851, Fig. 2D, respectively).

Fig. 2.
Hematocrit and hemoglobin values were decreased in marmosets with WMS. (A) Hematocrit values and (B) hemoglobin values of marmosets in the WMS and control groups. Solid horizontal lines indicate mean values for each group. Correlations between (C) body weight ...

The platelet value was also significantly different between the two groups (P<0.01, Fig. 2E). The mean platelet values of the WMS group and control group were 118.3 ± 11.61 × 104/µl and 45.9 ± 4.36 × 104/µl, respectively. Platelet values showed a significant negative correlation with body weight (P<0.01, rs=−0.695, Fig. 2F).

Although there was also a significant difference between the two groups in red blood cell values (mean 335.4 ± 80.75 × 104/µl in the MWS group and 618.9 ± 66.04 × 104/µl in the control group, P<0.01), there was no significant difference (P>0.05) between the groups in MCV (mean 67.8 ± 0.82 fl in the WMS group and 65.8 ± 1.74 fl in the control group), MCH (mean 22.4 ± 0.87 pg in the WMS group and 21.0 ± 0.34 pg in the control group), MCHC (mean 33.2 ± 1.42 g/dl in the WMS group and 31.9 ± 0.16 g/dl in the control group) or white blood cell values (mean 71.4 ± 28.23 × 102/µl in the MWS group and 57.9 ± 7.30 × 104/µl in the control group).

Serum chemistry test: The levels of serum albumin differed significantly between animals in the two groups (P<0.01, Fig. 3A). The mean albumin levels in the WMS and control groups were 3.49 ± 0.221 g/dl and 5.53 ± 0.300 g/dl, respectively. A significant correlation between body weight and serum albumin level was observed (P<0.01, rs=0.879, Fig. 3B).

Fig. 3.
Serum albumin and serum calcium values were decreased in marmosets with WMS. (A) Serum albumin values and (B) serum calcium values of marmosets in the WMS and control groups. Solid horizontal lines represent mean values for each group. Correlations between ...

Similarly, the levels of serum calcium differed significantly between animals in the two groups (P<0.01, Fig. 3C). The mean calcium levels in the WMS and control groups were 8.8 ± 0.40 mg/dl and 11.3 ± 0.56 mg/dl, respectively. A significant correlation between body weight and serum calcium level was observed (P<0.01, rs=0.734, Fig. 3D).

Serum MMP9 concentration: There was a significant difference in serum MMP9 concentration between the two groups (P<0.01, Fig. 4A). The mean MMP9 concentrations in the WMS and control groups were 91.7 ± 21.79 ng/ml and 17.4 ± 2.73 ng/ml, respectively. A significant negative correlation between body weight and serum MMP9 concentration was observed (P<0.05, rs=−0.660, Fig. 4B).

Fig. 4.
Blood MMP9 values are increased in marmosets with WMS. (A) Blood MMP9 values of marmosets in the WMS and control groups. Solid horizontal lines represent mean values for each group. (B) Correlations between body weight, and blood MMP9 values in individual ...

Bowel section of animals in the WMS group: There were no polyps or cancer in the colons in either the WMS or control group (data not shown). Epithelial damage and disruption of crypt architecture were observed in the transverse colon samples (Fig. 5A and 5B) and ascending colon samples (Fig. 5C and 5D). The colonic tissues revealed inflammatory cell infiltration in the lamina propria of the mucosa, atrophy of intestinal villus and decreased numbers of goblet cells (Fig. 5B and 5D). There were no abnormalities in the colons in the control group (data not shown).

Fig. 5.
Representative photomicrographs of sections of the colon in marmosets with WMS. (A) Transverse colon. Scale bar: 100 µm. (B) Ascending colon. Scale bar: 100 µm. (C) Magnification of the black square in A. Scale bar: 50 µm. (D) ...


Common marmosets are often used for long-term research experiments, such as behavioral analysis, in the field of brain science [2]. A long duration is needed for the production of transgenic marmosets, at least 5 months for the duration of pregnancy and a litter size of 2–4 infants, so each animal is very valuable.

WMS can occur in any animal used for ongoing research. Due to this morbidity and mortality, the disease is a large risk factor for wasted research resources. It was reported that some treatments, such as long-term administration of steroids with relatively few side effects, such as budesonide, can cause temporary remission [27]. However, because steroid treatment is relatively ineffective in animals in the terminal stage and is not persistent, steroid treatment cannot be said to be adequate. Thus, early identification of diseased animals, removal from experiments and prompt treatment of these animals are important.

As other reports have mentioned, alopecia [18, 25], pigeon-toe [18, 25], anemia [18], thrombocytosis [18], hypoalbuminemia [2, 18] and hypocalcemia [2] were also observed in the WMS group in this study. These results support the hypothesis that hematocrit, hemoglobin, platelets, serum albumin and serum calcium can be used for the diagnosis of WMS.

It was suggested that the anemia and hypoalbuminemia seen in the animals reflect poor nutritional condition, caused by an uptake disorder or protein and/or iron absorption defect. However, because no significant difference or even trend was seen in MCV, MCH or MCHC between the WMS and control groups, we suggest that the anemia and hypoalbuminemia observed in this study were due to other factor(s) depending on the individuals. Anemia is a major symptom of IBD in humans [13, 29], and iron deficiency is the largest contributing factor. However, it has been suggested that erythropoietin depression [17], vitamin insufficiency [13] and autoimmune hemolytic disease in IBD patients [24] could also cause anemia. Given that several factors other than iron deficiency could have caused anemia in WMS, similar to the situation in human IBD, further investigation is needed.

It is known that MMPs function to process several inflammatory cytokines, including tumor necrosis factor alpha (TNF-α) [10]. MMP9 is thought to be the main metalloproteinase implicated in the development of IBD [32], and the increase in MMP9 in mouse and rat IBD has been reported [4, 22]. Although there are other biomarkers used for diagnosis of IBD, such as C-reactive proteins (CRP) or erythrocyte sedimentation rate (ESR), it was reported that MMP9 is a more useful biomarker for diagnosis of human IBD than other biochemical markers in terms of that MMP9 can reflect disease state because MMP9 has much higher specificity in distinguishing between active IBD and inactive IBD than other parameters [23]. In our study, the WMS group showed significantly increased serum MMP9 concentrations, suggesting that MMP9 is connected with the pathological condition of WMS. Our results suggest that serum MMP9 might have an important role in the mechanism of WMS and could be useful for the diagnosis of WMS. A MMP9-targeted inhibitor was developed in rats and is hoped to be a specific medicine for IBD [22]. MMP9 might also be a target for the treatment of WMS. To our knowledge, this is the first report of increased MMP9 levels in marmosets with WMS. We previously reported that fecal calprotectin can be a marker for detecting colonic inflammation [25], and it was reported that fecal MMP9 can be used for detecting human IBD as well as fecal calprotectin [15]. So, further investigations of fecal MMP9 as a marker for detecting WMS should be performed. We propose that the WMS marmoset could be an animal model of human IBD with respect to MMP9. Further investigations of other molecules involved in human IBD need to be performed in marmosets to explore this possibility. TNF-α and interleukin-6 (IL-6) are major cytokines in inflammation, and there is a report regarding the involvement of TNF-α and IL-6 in human autoimmune diseases, including IBD [28]. Although TNF-α and IL-6 might be involved in WMS, little has been reported on the behavior of this molecule. Because it is known that MMP9 is regulated by IL-6 [16] and affects TNF-α [10], future experiments aimed at investigating the relationship between MMP9 and TNF-α, or IL-6 in WMS are needed.


We thank Dr. Chitoshi Itakura for providing the opportunity to perform the present study. We also thank the rearing staff of the animal facility for their generous help.


1. Abbott D. H., Barnett D. K., Colman R. J., Yamamoto M. E., Schultz-Darken N. J. 2003. Aspects of common marmoset basic biology and life history important for biomedical research. Comp. Med. 53: 339–350. [PubMed]
2. Baxter V. K., Shaw G. C., Sotuyo N. P., Carlson C. S., Olson E. J., Zink M. C., Mankowski J. L., Adams R. J., Hutchinson E. K., Metcalf Pate K. A. 2013. Serum albumin and body weight as biomarkers for the antemortem identification of bone and gastrointestinal disease in the common marmoset. PLoS ONE 8: e82747. doi: 10.1371/journal.pone.0082747 [PMC free article] [PubMed] [Cross Ref]
3. ’t Hart B. A., Abbott D. H., Nakamura K., Fuchs E. 2012. The marmoset monkey: a multi-purpose preclinical and translational model of human biology and disease. Drug Discov. Today 17: 1160–1165. doi: 10.1016/j.drudis.2012.06.009 [PubMed] [Cross Ref]
4. Castaneda F. E., Walia B., Vijay-Kumar M., Patel N. R., Roser S., Kolachala V. L., Rojas M., Wang L., Oprea G., Garg P., Gewirtz A. T., Roman J., Merlin D., Sitaraman S. V. 2005. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 129: 1991–2008. doi: 10.1053/j.gastro.2005.09.017 [PubMed] [Cross Ref]
5. Chalifoux L. V., Bronson R. T., Escajadillo A., McKenna S. 1982. An analysis of the association of gastroenteric lesions with chronic wasting syndrome of marmosets. Vet. Pathol. Suppl. 7: 141–162. doi: 10.1177/030098588201907s11 [PubMed] [Cross Ref]
6. Chen L. C., Noelken M. E., Nagase H. 1993. Disruption of the cysteine-75 and zinc ion coordination is not sufficient to activate the precursor of human matrix metalloproteinase 3 (stromelysin 1). Biochemistry 32: 10289–10295. doi: 10.1021/bi00090a003 [PubMed] [Cross Ref]
7. Donna I., Andrew J. B. 1995. Results of a preliminary survey into wasting marmoset syndrome in Callitrichid collections. pp.148–158. In: Proc. Ann. Conf. Nutr. Adv. Group 1, Guild Inn, Toronto.
8. Elkington P. T., Friedland J. S. 2006. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 61: 259–266. doi: 10.1136/thx.2005.051979 [PMC free article] [PubMed] [Cross Ref]
9. Flores A. I., Gómez-Gómez G. J., Masedo-González Á., Martínez-Montiel M. P. 2015. Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy? World J Stem Cells 7: 343–351. doi: 10.4252/wjsc.v7.i2.343 [PMC free article] [PubMed] [Cross Ref]
10. Gearing A. J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A. H., Drummond A. H., Galloway W. A., Gilbert R., Gordon J. L., Kber J. L., Leber T. M., Mangan M., Miller K., Nayee P., Owen K., Patel S., Thomas W., Wells G., Wood L. M., Woolley K. 1994. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 370: 555–557. doi: 10.1038/370555a0 [PubMed] [Cross Ref]
11. Gerlach K., Hwang Y., Nikolaev A., Atreya R., Dornhoff H., Steiner S., Lehr H. A., Wirtz S., Vieth M., Waisman A., Rosenbauer F., McKenzie A. N., Weigmann B., Neurath M. F. 2014. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat. Immunol. 15: 676–686. doi: 10.1038/ni.2920 [PubMed] [Cross Ref]
12. Gore M. A., Brandes F., Kaup F. J., Lenzner R., Mothes T., Osman A. A. 2001. Callitrichid nutrition and food sensitivity. J. Med. Primatol. 30: 179–184. doi: 10.1111/j.1600-0684.2001.tb00007.x [PubMed] [Cross Ref]
13. Hoffbrand A. V., Stewart J. S., Booth C. C., Mollin D. L. 1968. Folate deficiency in Crohn’s disease: incidence, pathogenesis, and treatment. BMJ 2: 71–75. doi: 10.1136/bmj.2.5597.71 [PMC free article] [PubMed] [Cross Ref]
14. Imai K., Yokohama Y., Nakanishi I., Ohuchi E., Fujii Y., Nakai N., Okada Y. 1995. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J. Biol. Chem. 270: 6691–6697. doi: 10.1074/jbc.270.12.6691 [PubMed] [Cross Ref]
15. Kolho K. L., Sipponen T., Valtonen E., Savilahti E. 2014. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int. J. Colorectal Dis. 29: 43–50. doi: 10.1007/s00384-013-1775-9 [PubMed] [Cross Ref]
16. Kossakowska A. E., Edwards D. R., Prusinkiewicz C., Zhang M. C., Guo D., Urbanski S. J., Grogan T., Marquez L. A., Janowska-Wieczorek A. 1999. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin’s lymphomas. Blood 94: 2080–2089. [PubMed]
17. Kulnigg S., Gasche C. 2006. Systematic review: managing anaemia in Crohn’s disease. Aliment. Pharmacol. Ther. 24: 1507–1523. doi: 10.1111/j.1365-2036.2006.03146.x [PubMed] [Cross Ref]
18. Logan A. C., Khan K. N. 1996. Clinical pathologic changes in two marmosets with wasting syndrome. Toxicol. Pathol. 24: 707–709. doi: 10.1177/019262339602400605 [PubMed] [Cross Ref]
19. Ludlage E., Mansfield K. 2003. Clinical care and diseases of the common marmoset (Callithrix jacchus). Comp. Med. 53: 369–382. [PubMed]
20. Lyons J. G., Birkedal-Hansen B., Pierson M. C., Whitelock J. M., Birkedal-Hansen H. 1993. Interleukin-1 beta and transforming growth factor-alpha/epidermal growth factor induce expression of M(r) 95,000 type IV collagenase/gelatinase and interstitial fibroblast-type collagenase by rat mucosal keratinocytes. J. Biol. Chem. 268: 19143–19151. [PubMed]
21. Mansfield K. 2003. Marmoset models commonly used in biomedical research. Comp. Med. 53: 383–392. [PubMed]
22. Mao J. W., He X. M., Tang H. Y., Wang Y. D. 2012. Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats. World J. Gastroenterol. 18: 7063–7069. doi: 10.3748/wjg.v18.i47.7063 [PMC free article] [PubMed] [Cross Ref]
23. Matusiewicz M., Neubauer K., Mierzchala-Pasierb M., Gamian A., Krzystek-Korpacka M. 2014. Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases. Dis. Markers 2014: 643645. doi: 10.1155/2014/643645 [PMC free article] [PubMed] [Cross Ref]
24. Murphy P. T., Cunney R., Nolan A., O’Donnell J. R. 1996. Autoimmune haemolytic anaemia associated with ulcerative colitis. Ir. Med. J. 89: 172–173. [PubMed]
25. Nakashima E., Okano Y., Niimi K., Takahashi E. 2013. Detection of calprotectin and apoptotic activity in the colon of marmosets with chronic diarrhea. J. Vet. Med. Sci. 75: 1633–1636. doi: 10.1292/jvms.13-0257 [PMC free article] [PubMed] [Cross Ref]
26. Okano H., Miyawaki A., Kasai K. 2015. Brain/MINDS: brain-mapping project in Japan. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370: 370. doi: 10.1098/rstb.2014.0310 [PMC free article] [PubMed] [Cross Ref]
27. Otovic P., Smith S., Hutchinson E. 2015. The use of glucocorticoids in marmoset wasting syndrome. J. Med. Primatol. 44: 53–59. doi: 10.1111/jmp.12159 [PMC free article] [PubMed] [Cross Ref]
28. Reimund J. M., Wittersheim C., Dumont S., Muller C. D., Kenney J. S., Baumann R., Poindron P., Duclos B. 1996. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease. Gut 39: 684–689. doi: 10.1136/gut.39.5.684 [PMC free article] [PubMed] [Cross Ref]
29. Reinisch W., Staun M., Tandon R. K., Altorjay I., Thillainayagam A. V., Gratzer C., Nijhawan S., Thomsen L. L. 2013. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am. J. Gastroenterol. 108: 1877–1888. doi: 10.1038/ajg.2013.335 [PMC free article] [PubMed] [Cross Ref]
30. Remington E. D., Osmanski M. S., Wang X. 2012. An operant conditioning method for studying auditory behaviors in marmoset monkeys. PLoS ONE 7: e47895. doi: 10.1371/journal.pone.0047895 [PMC free article] [PubMed] [Cross Ref]
31. Sandborn W. J., Feagan B. G., Fedorak R. N., Scherl E., Fleisher M. R., Katz S., Johanns J., Blank M., Rutgeerts P., Ustekinumab Crohn’s Disease Study Group2008. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 135: 1130–1141. doi: 10.1053/j.gastro.2008.07.014 [PubMed] [Cross Ref]
32. Santana A., Medina C., Paz-Cabrera M. C., Díaz-Gonzalez F., Farré E., Salas A., Radomski M. W., Quintero E. 2006. Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J. Gastroenterol. 12: 6464–6472. [PMC free article] [PubMed]
33. Sasaki E., Suemizu H., Shimada A., Hanazawa K., Oiwa R., Kamioka M., Tomioka I., Sotomaru Y., Hirakawa R., Eto T., Shiozawa S., Maeda T., Ito M., Ito R., Kito C., Yagihashi C., Kawai K., Miyoshi H., Tanioka Y., Tamaoki N., Habu S., Okano H., Nomura T. 2009. Generation of transgenic non-human primates with germline transmission. Nature 459: 523–527. doi: 10.1038/nature08090 [PubMed] [Cross Ref]
34. Silverberg M. S., Satsangi J., Ahmad T., Arnott I. D., Bernstein C. N., Brant S. R., Caprilli R., Colombel J. F., Gasche C., Geboes K., Jewell D. P., Karban A., Loftus E. V., Jr, Peña A. S., Riddell R. H., Sachar D. B., Schreiber S., Steinhart A. H., Targan S. R., Vermeire S., Warren B. F. 2005. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol.19: Suppl A: 5A–36A. [PubMed]
35. Tardif S. D., Mansfield K. G., Ratnam R., Ross C. N., Ziegler T. E. 2011. The marmoset as a model of aging and age-related diseases. ILAR J. 52: 54–65. doi: 10.1093/ilar.52.1.54 [PMC free article] [PubMed] [Cross Ref]
36. Tardif S. D., Smucny D. A., Abbott D. H., Mansfield K., Schultz-Darken N., Yamamoto M. E. 2003. Reproduction in captive common marmosets (Callithrix jacchus). Comp. Med. 53: 364–368. [PubMed]
37. Van der Marel S., Majowicz A., van Deventer S., Petry H., Hommes D. W., Ferreira V. 2011. Gene and cell therapy based treatment strategies for inflammatory bowel diseases. World J. Gastrointest. Pathophysiol. 15: 114–122. doi: 10.4291/wjgp.v2.i6.114 [PMC free article] [PubMed] [Cross Ref]
38. Williams I. R. 2004. Chemokine receptors and leukocyte trafficking in the mucosal immune system. Immunol. Res. 29: 283–292. doi: 10.1385/IR:29:1-3:283 [PubMed] [Cross Ref]

Articles from The Journal of Veterinary Medical Science are provided here courtesy of Japanese Society of Veterinary Science